This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Springer, B.
Right arrow Articles by Böttger, E. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Springer, B.
Right arrow Articles by Böttger, E. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2009, p. 1773-1780, Vol. 47, No. 6
0095-1137/09/$08.00+0     doi:10.1128/JCM.02501-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis by Use of MGIT 960 and EpiCenter Instrumentation {triangledown}

Burkhard Springer,1,2,3 Katja Lucke,1,2 Romana Calligaris-Maibach,1,2 Claudia Ritter,1,2 and Erik C. Böttger1,2*

Institut für Medizinische Mikrobiologie, Universität Zürich,1 Nationales Zentrum für Mykobakterien, CH-8006 Zürich, Switzerland,2 Institut für Medizinische Mikrobiologie und Hygiene, Österreichische Agentur für Gesundheit und Ernährungssicherheit, A-8010 Graz, Austria3

Received 30 December 2008/ Returned for modification 9 February 2009/ Accepted 21 March 2009

Since numbers of drug-resistant Mycobacterium tuberculosis strains are on the rise, the simple classification into "susceptible" and "resistant" strains based on susceptibility testing at "critical concentrations" has to be reconsidered. While future studies have to address the correlation of phenotypic resistance levels and treatment outcomes, a prerequisite for corresponding investigations is the ability to exactly determine levels of quantitative drug resistance in clinical M. tuberculosis isolates. Here we have established the conditions for quantitative drug susceptibility testing for first- and second-line agents using MGIT 960 instrumentation and EpiCenter software equipped with the TB eXiST module. In-depth comparative analysis of a range of well-characterized susceptible and resistant clinical isolates has allowed us to propose conditions for testing and to develop criteria for interpretation.

* Corresponding author. Mailing address: Institut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, CH-8006 Zürich, Switzerland. Phone: 41 44 634 26 60. Fax: 41 44 634 49 06. E-mail: boettger{at}imm.uzh.ch

{triangledown} Published ahead of print on 1 April 2009.

Journal of Clinical Microbiology, June 2009, p. 1773-1780, Vol. 47, No. 6
0095-1137/09/$08.00+0     doi:10.1128/JCM.02501-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»